Status:
COMPLETED
Pediatric Open-Label Extension Study of Etanercept in Patients With Plaque Psoriasis
Lead Sponsor:
Amgen
Conditions:
Pediatric Plaque Psoriasis
Eligibility:
All Genders
Phase:
PHASE3
Brief Summary
The purpose of this study is to evaluate the long-term safety and efficacy of etanercept in pediatric patients with moderate to severe psoriasis.
Detailed Description
This study was a multicenter, open-label extension study for pediatric patients who participated in Study 20030211 (NCT00078819).
Eligibility Criteria
Inclusion
- Enrollment on previous Amgen study 20030211 (NCT00078819)
Exclusion
- Serious or clinically significant adverse event on Amgen study 20030211 related to etanercept
Key Trial Info
Start Date :
August 11 2005
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
August 16 2017
Estimated Enrollment :
182 Patients enrolled
Trial Details
Trial ID
NCT00141921
Start Date
August 11 2005
End Date
August 16 2017
Last Update
October 5 2017
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.